KKR struck an agreement to acquire Integer Holdings for $5.7 billion in cash, removing one of the largest independent medical device component manufacturers from public markets. The deal—announced without a disclosed per-share price—consolidates upstream supply in cardiac rhythm management and neuromodulation at a time when device OEMs face margin pressure and regulatory scrutiny. Integer, headquartered in Plano, generates roughly $1.6 billion in annual revenue supplying batteries, capacitors, and miniaturized components to firms including Medtronic, Abbott, and Boston Scientific.

The transaction marks KKR's return to mid-cap medtech after a two-year pause. Integer's enterprise value implies an estimated 10x-11x trailing EBITDA multiple, a 15-20 percent premium to comps in the medical technology supply chain but below the 12-14x range KKR paid for Envision Healthcare in 2018. Integer's board approved the offer unanimously. The company had traded near $95 per share in early 2025 before falling to the $75-$80 range on concerns about elective procedure volumes and component margin compression. KKR's bid likely lands in the $105-$115 per share corridor, based on the aggregate deal value and Integer's 52 million shares outstanding. Close is expected in Q4 2026 or Q1 2027, subject to regulatory clearance and shareholder approval.

The strategic angle is vertical integration by proxy. Integer sits upstream of the large-cap device makers but lacks their scale in R&D and direct hospital relationships. By taking it private, KKR can rationalize the cost base, invest in next-generation miniaturized power systems for rechargeable neuromodulation devices, and potentially combine Integer with portfolio assets in adjacent spaces. The firm already owns Cotiviti (healthcare analytics) and a stake in Envision's successor entities. If KKR merges Integer with another captive supplier or rolls it into a broader medtech platform, the deal becomes an arbitrage on public-market risk aversion and a bet that device volumes stabilize in 2027 as procedure backlogs clear.

For allocators, watch three things. First, whether Abbott or Boston Scientific move to secure alternative supply or acquire smaller component shops in the $300-$800 million range before year-end. Second, how KKR finances the deal—if it leans heavily on subscription credit facilities or co-invest from sovereign LPs, that signals confidence in near-term cash conversion. Third, whether Integer's largest customers renegotiate supply agreements before close; any price reset would flow directly to post-close EBITDA and affect KKR's 2027-2029 refinancing options.

Integer's stock will likely gap to within 2-3 percent of the undisclosed offer price by Tuesday morning, erasing the arbitrage window for deal-spread funds. The play now is not the equity but the leverage: if KKR layers $2.8-$3.2 billion of debt at 275-325 bps over SOFR, the term loan B tranches will trade at 98-99 cents on syndication and tighten to par within six months if device volumes hold.